(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Aileron Therapeutics, Datadog, and Matterport
.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Aileron Therapeutics (ALRN) | 1.54 | 32.76% | 2023-11-07 01:10:05 |
| 2 | Datadog (DDOG) | 103.60 | 30.23% | 2023-11-07 12:15:57 |
| 3 | Matterport (MTTR) |
2.58 | 21.46% | 2023-11-07 12:22:54 |
| 4 | Matterport (MTTR) |
2.58 | 21.46% | 2023-11-07 12:22:54 |
| 5 | MongoDB (MDB) | 375.71 | 13.05% | 2023-11-07 12:16:29 |
| 6 | Fiverr (FVRR) | 24.27 | 12.05% | 2023-11-07 13:00:59 |
| 7 | Aravive (ARAV) | 0.15 | 10.36% | 2023-11-07 05:11:05 |
| 8 | ALX Oncology Holdings (ALXO) | 8.96 | 7.69% | 2023-11-07 01:17:05 |
| 9 | Expedia Group (EXPE) | 120.17 | 7.69% | 2023-11-07 12:11:55 |
| 10 | DISH Network (DISH) | 3.69 | 7.28% | 2023-11-07 12:11:36 |
The three biggest losers today are Annexon, Aptevo Therapeutics, and Alpine Immune Sciences.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Annexon (ANNX) | 2.20 | -15.06% | 2023-11-07 03:14:05 |
| 2 | Aptevo Therapeutics (APVO) | 0.22 | -14.3% | 2023-11-07 05:06:06 |
| 3 | Alpine Immune Sciences (ALPN) | 14.13 | -12.07% | 2023-11-07 01:08:05 |
| 4 | Air Products and Chemicals (APD) | 258.08 | -11.4% | 2023-11-07 12:52:26 |
| 5 | BIO-key International (BKYI) | 0.21 | -10.53% | 2023-11-07 11:48:06 |
| 6 | AquaBounty Technologies (AQB) | 2.67 | -9.49% | 2023-11-07 05:08:05 |
| 7 | Allakos (ALLK) | 2.04 | -9.33% | 2023-11-07 01:06:05 |
| 8 | Atomera Incorporated (ATOM) | 5.32 | -8.99% | 2023-11-07 07:15:05 |
| 9 | Akoustis Technologies (AKTS) | 0.59 | -8.92% | 2023-11-06 23:13:05 |
| 10 | POSCO (PKX) | 88.56 | -8.7% | 2023-11-07 12:21:28 |
Winners today
1. Aileron Therapeutics (ALRN) – 32.76%
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
NASDAQ ended the session with Aileron Therapeutics jumping 32.76% to $1.54 on Wednesday, after two sequential sessions in a row of gains. NASDAQ jumped 0.9% to $13,639.86, after five sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Aileron Therapeutics has a trailing twelve months EPS of $-3.78.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.36%.
Volume
Today’s last reported volume for Aileron Therapeutics is 571383 which is 1785.88% above its average volume of 30298.
Yearly Top and Bottom Value
Aileron Therapeutics’s stock is valued at $1.54 at 01:32 EST, way under its 52-week high of $4.12 and way higher than its 52-week low of $1.01.
More news about Aileron Therapeutics.
2. Datadog (DDOG) – 30.23%
Datadog, Inc. operates an observability and security platform for cloud applications in North America and internationally. The company's products include infrastructure and application performance monitoring, log management, digital experience monitoring, continuous profiler, database monitoring, network monitoring, incident management, observability pipelines, cloud cost management, universal service monitoring, cloud security management, application security management. cloud SIEM, sensitive data scanner, and CI Visibility. The company was incorporated in 2010 and is headquartered in New York, New York.
NASDAQ ended the session with Datadog rising 30.23% to $103.60 on Wednesday, following the last session’s downward trend. NASDAQ jumped 0.9% to $13,639.86, after five consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Datadog has a trailing twelve months EPS of $-0.27.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25.4%, now sitting on 1.9B for the twelve trailing months.
Sales Growth
Datadog’s sales growth is 26.5% for the current quarter and 15.8% for the next.
Previous days news about Datadog
- : snowflake, mongodb shares rally sharply after datadog earnings. According to MarketWatch on Tuesday, 7 November, "Shares of Snowflake Inc. , MongoDB Inc. and Elastic NV were all rallying sharply in Tuesday’s premarket trading after Datadog Inc.’s upbeat earnings report eased fears about consumption-based software companies for the latest quarter. "
- Should you invest in datadog (ddog) based on bullish wall street views?. According to Zacks on Tuesday, 7 November, "Check price target & stock forecast for Datadog here>>>The ABR suggests buying Datadog, but making an investment decision solely on the basis of this information might not be a good idea. ", "Therefore, the Buy-equivalent ABR for Datadog may serve as a useful guide for investors."
More news about Datadog.
3. Matterport
(MTTR) – 21.46%
Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Smartphone Capture, a smartphone capture solution for both iOS and Android; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; and 360 Cameras. It also provides Matterport Axis, a motorized mount that can be used with the Matterport Capture app to capture 3D digital twins of any physical space with increased speed, precision, and consistency. It offers solutions for residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality. Matterport, Inc. is headquartered in Sunnyvale, California.
NASDAQ ended the session with Matterport
jumping 21.46% to $2.58 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.9% to $13,639.86, after five sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Matterport
has a trailing twelve months EPS of $-0.73.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.72%.
Yearly Top and Bottom Value
Matterport
‘s stock is valued at $2.58 at 01:32 EST, way under its 52-week high of $4.07 and way higher than its 52-week low of $1.84.
Moving Average
Matterport
‘s worth is way higher than its 50-day moving average of $2.29 and under its 200-day moving average of $2.80.
Volatility
Matterport
‘s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.61%, a negative 0.25%, and a positive 2.80%.
Matterport
‘s highest amplitude of average volatility was 4.63% (last week), 3.36% (last month), and 2.80% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Matterport
‘s EBITDA is -9.08.
More news about Matterport
.
4. Matterport
(MTTR) – 21.46%
Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Smartphone Capture, a smartphone capture solution for both iOS and Android; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; and 360 Cameras. It also provides Matterport Axis, a motorized mount that can be used with the Matterport Capture app to capture 3D digital twins of any physical space with increased speed, precision, and consistency. It offers solutions for residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality. Matterport, Inc. is headquartered in Sunnyvale, California.
NASDAQ ended the session with Matterport
jumping 21.46% to $2.58 on Wednesday while NASDAQ jumped 0.9% to $13,639.86.
Earnings Per Share
As for profitability, Matterport
has a trailing twelve months EPS of $-0.73.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.72%.
Volatility
Matterport
‘s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.61%, a negative 0.25%, and a positive 2.80%.
Matterport
‘s highest amplitude of average volatility was 4.63% (last week), 3.36% (last month), and 2.80% (last quarter).
Sales Growth
Matterport
‘s sales growth is 8.9% for the current quarter and negative 2.2% for the next.
More news about Matterport
.
5. MongoDB (MDB) – 13.05%
MongoDB, Inc. provides general purpose database platform worldwide. The company offers MongoDB Atlas, a hosted multi-cloud database-as-a-service solution; MongoDB Enterprise Advanced, a commercial database server for enterprise customers to run in the cloud, on-premise, or in a hybrid environment; and Community Server, a free-to-download version of its database, which includes the functionality that developers need to get started with MongoDB. It also provides professional services comprising consulting and training. The company was formerly known as 10gen, Inc. and changed its name to MongoDB, Inc. in August 2013. MongoDB, Inc. was incorporated in 2007 and is headquartered in New York, New York.
NASDAQ ended the session with MongoDB jumping 13.05% to $375.71 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.9% to $13,639.86, after five sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, MongoDB has a trailing twelve months EPS of $-3.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.04%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 121.7% and a drop 35.1% for the next.
Sales Growth
MongoDB’s sales growth for the next quarter is 14.8%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 39.6%, now sitting on 1.49B for the twelve trailing months.
Volatility
MongoDB’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.13%, a negative 0.16%, and a positive 2.14%.
MongoDB’s highest amplitude of average volatility was 2.99% (last week), 2.21% (last month), and 2.14% (last quarter).
Previous days news about MongoDB
- : snowflake, mongodb shares rally sharply after datadog earnings. According to MarketWatch on Tuesday, 7 November, "Shares of Snowflake Inc. , MongoDB Inc. and Elastic NV were all rallying sharply in Tuesday’s premarket trading after Datadog Inc.’s upbeat earnings report eased fears about consumption-based software companies for the latest quarter. ", "Snowflake shares were up more than 8%, while MongoDB shares were up about 6% and Elastic shares were ahead about 4%. "
More news about MongoDB.
6. Fiverr (FVRR) – 12.05%
Fiverr International Ltd. operates an online marketplace worldwide. Its platform enables sellers to sell their services and buyers to buy them. The company's platform includes approximately 600 categories in ten verticals, including graphic and design, digital marketing, writing and translation, video and animation, music and audio, programming and tech, business, data, lifestyle, and photography. It also offers Fiverr Workspace, which provides freelancers a software solution to manage invoicing, contracts, time tracking, and organizing workflow; Fiverr Learn and CreativeLive that offers learning and development offerings for freelancers; ClearVoice, a subscription based content marketing solution; and Stoke Talent, a freelancer management system. In addition, the company provides back office and creative talent platforms. Its buyers include businesses of various sizes, as well as sellers comprise a group of freelancers and small businesses. The company was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
NYSE ended the session with Fiverr jumping 12.05% to $24.27 on Wednesday while NYSE slid 0.35% to $15,386.01.
Earnings Per Share
As for profitability, Fiverr has a trailing twelve months EPS of $-0.45.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.19%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 109.5% and 73.1%, respectively.
More news about Fiverr.
7. Aravive (ARAV) – 10.36%
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
NASDAQ ended the session with Aravive rising 10.36% to $0.15 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ jumped 0.9% to $13,639.86, after five consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Aravive has a trailing twelve months EPS of $-1.3.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1497.43%.
Moving Average
Aravive’s value is higher than its 50-day moving average of $0.14 and way under its 200-day moving average of $1.20.
Yearly Top and Bottom Value
Aravive’s stock is valued at $0.15 at 01:32 EST, way under its 52-week high of $2.46 and way above its 52-week low of $0.11.
More news about Aravive.
8. ALX Oncology Holdings (ALXO) – 7.69%
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
NASDAQ ended the session with ALX Oncology Holdings rising 7.69% to $8.96 on Wednesday, after five sequential sessions in a row of gains. NASDAQ jumped 0.9% to $13,639.86, after five consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, ALX Oncology Holdings has a trailing twelve months EPS of $-3.44.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -49.29%.
Volume
Today’s last reported volume for ALX Oncology Holdings is 467157 which is 62.01% below its average volume of 1229870.
More news about ALX Oncology Holdings.
9. Expedia Group (EXPE) – 7.69%
Expedia Group, Inc. operates as an online travel company in the United States and internationally. The company operates through Retail, B2B, and trivago segments. Its brand portfolio includes Brand Expedia, a full-service online travel brand with localized websites; Hotels.com for marketing and distributing lodging accommodations; Vrbo, an online marketplace for the alternative accommodations; Orbitz; Travelocity; Wotif Group; CheapTickets; ebookers; Expedia; Hotwire; CarRentals.com; Classic Vacations; and Expedia Cruise. The company's brand portfolio also comprises Expedia Partner Solutions, that offers private label and co-branded products through third-party websites; and Egencia that provides travel services to businesses and corporate customers. In addition, its brand portfolio consists of Trivago, a hotel metasearch website, which send referrals to online travel companies and travel service providers from hotel metasearch websites. Further, the company provides loyalty programs, hotel accommodations and alternative accommodations, and advertising and media services. It serves leisure and corporate travelers, that includes travel agencies, tour operators, travel supplier direct websites and call centers, consolidators and wholesalers of travel products and services, online portals and search websites, travel metasearch websites, mobile travel applications, and social media websites, as well as traditional consumer ecommerce and group buying websites. The company was formerly known as Expedia, Inc. and changed its name to Expedia Group, Inc. in March 2018. Expedia Group, Inc. was founded in 1996 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Expedia Group jumping 7.69% to $120.17 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.9% to $13,639.86, after five sequential sessions in a row of gains, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Expedia Group has a trailing twelve months EPS of $5.46.
PE Ratio
Expedia Group has a trailing twelve months price to earnings ratio of 22.01. Meaning, the purchaser of the share is investing $22.01 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.9%.
Volatility
Expedia Group’s last week, last month’s, and last quarter’s current intraday variation average was 6.12%, 0.65%, and 1.69%.
Expedia Group’s highest amplitude of average volatility was 7.56% (last week), 2.66% (last month), and 1.69% (last quarter).
Moving Average
Expedia Group’s worth is way above its 50-day moving average of $102.27 and way above its 200-day moving average of $104.08.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 23.2% and 47.6%, respectively.
Volume
Today’s last reported volume for Expedia Group is 2475510 which is 10.46% above its average volume of 2241040.
More news about Expedia Group.
10. DISH Network (DISH) – 7.28%
DISH Network Corporation, together with its subsidiaries, provides pay-TV services in the United States. The company operates in two segments, Pay-TV and Wireless. It offers video services under the DISH TV brand; and programming packages that include programming through national broadcast networks, local broadcast networks, and national and regional cable networks, as well as regional and specialty sports channels, premium movie channels, and Latino and international programming packages. The company also provides access to movies and television shows through TV or Internet-connected devices; and dishanywhere.com and mobile applications on Internet-connected devices to view authorized content, search program listings, and remotely control certain features of their DVRs. In addition, it offers Sling TV services, including Sling domestic, Sling International, Sling Latino, Sling Orange, and Sling Blue services that require an internet connection and are available on streaming-capable devices, such as streaming media devices, TVs, tablets, computers, game consoles, and phones, as well as market SLING TV services to consumers who do not subscribe to traditional satellite and cable pay-TV services. Further, the company provides wireless subscribers consumer plans with no annual service contracts, as well as monthly service plans, including high-speed data and unlimited talk and text. The company offers receiver systems and programming through direct sales channels, as well as independent third parties, such as small retailers, direct marketing groups, local and regional consumer electronics stores, retailers, and telecommunications companies. DISH Network Corporation was founded in 1980 and is headquartered in Englewood, Colorado.
NASDAQ ended the session with DISH Network rising 7.28% to $3.69 on Wednesday while NASDAQ rose 0.9% to $13,639.86.
Earnings Per Share
As for profitability, DISH Network has a trailing twelve months EPS of $1.9.
PE Ratio
DISH Network has a trailing twelve months price to earnings ratio of 1.94. Meaning, the purchaser of the share is investing $1.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.31%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 7.1%, now sitting on 16.01B for the twelve trailing months.
Previous days news about DISH Network
- DISH network (dish) Q3 earnings miss, revenues decline y/y. According to Zacks on Tuesday, 7 November, "DISH Network Corporation price-consensus-eps-surprise-chart | DISH Network Corporation Quote", "As of Sep 30, 2023, DISH Network had cash, cash equivalents and current marketable investment securities of $1.035 billion compared with $1.78 billion as of Jun 30, 2023."
More news about DISH Network.
Losers Today
1. Annexon (ANNX) – -15.06%
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
NASDAQ ended the session with Annexon sliding 15.06% to $2.20 on Wednesday while NASDAQ rose 0.9% to $13,639.86.
Earnings Per Share
As for profitability, Annexon has a trailing twelve months EPS of $-1.71.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -81.24%.
More news about Annexon.
2. Aptevo Therapeutics (APVO) – -14.3%
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Aptevo Therapeutics falling 14.3% to $0.22 on Wednesday, after three successive sessions in a row of losses. NASDAQ rose 0.9% to $13,639.86, after five successive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Aptevo Therapeutics has a trailing twelve months EPS of $-3.49.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -97.17%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 50% and 38.9%, respectively.
Moving Average
Aptevo Therapeutics’s worth is way under its 50-day moving average of $0.35 and way under its 200-day moving average of $1.30.
More news about Aptevo Therapeutics.
3. Alpine Immune Sciences (ALPN) – -12.07%
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
NASDAQ ended the session with Alpine Immune Sciences falling 12.07% to $14.13 on Wednesday, following the last session’s downward trend. NASDAQ rose 0.9% to $13,639.86, after five consecutive sessions in a row of gains, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Alpine Immune Sciences has a trailing twelve months EPS of $-1.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.55%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 62.4%, now sitting on 29.12M for the twelve trailing months.
Volume
Today’s last reported volume for Alpine Immune Sciences is 962527 which is 118.13% above its average volume of 441249.
More news about Alpine Immune Sciences.
4. Air Products and Chemicals (APD) – -11.4%
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, equipment, and related services in the Americas, Asia, Europe, the Middle East, India, and internationally. The company produces atmospheric gases, including oxygen, nitrogen, and argon; process gases, such as hydrogen, helium, carbon dioxide, carbon monoxide, and syngas; specialty gases; and equipment for the production or processing of gases comprising air separation units and non-cryogenic generators for customers in various industries, including refining, chemical, manufacturing, electronics, magnetic resonance imaging, energy production, medical, food, and metals. It also designs and manufactures equipment for air separation, hydrocarbon recovery and purification, natural gas liquefaction, and liquid helium and liquid hydrogen transport and storage. The company was founded in 1940 and is headquartered in Allentown, Pennsylvania.
NYSE ended the session with Air Products and Chemicals dropping 11.4% to $258.08 on Wednesday while NYSE slid 0.35% to $15,386.01.
Earnings Per Share
As for profitability, Air Products and Chemicals has a trailing twelve months EPS of $9.79.
PE Ratio
Air Products and Chemicals has a trailing twelve months price to earnings ratio of 26.36. Meaning, the purchaser of the share is investing $26.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.04%.
Previous days news about Air Products and Chemicals
- Air products and chemicals (apd) Q4 earnings surpass estimates. According to Zacks on Tuesday, 7 November, "While Air Products and Chemicals has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Air products and chemicals (apd) Q4 earnings: how key metrics compare to wall street estimates. According to Zacks on Tuesday, 7 November, "Here is how Air Products and Chemicals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Air Products and Chemicals.
5. BIO-key International (BKYI) – -10.53%
BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premises SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions that develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.
NASDAQ ended the session with BIO-key International dropping 10.53% to $0.21 on Wednesday while NASDAQ rose 0.9% to $13,639.86.
Earnings Per Share
As for profitability, BIO-key International has a trailing twelve months EPS of $-1.1.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -127.35%.
More news about BIO-key International.
6. AquaBounty Technologies (AQB) – -9.49%
AquaBounty Technologies, Inc., a biotechnology company, focuses on improving productivity in the commercial aquaculture industry in the United States and Canada. It offers AquAdvantage Salmon, a bioengineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Maynard, Massachusetts.
NASDAQ ended the session with AquaBounty Technologies sliding 9.49% to $2.67 on Wednesday while NASDAQ jumped 0.9% to $13,639.86.
Earnings Per Share
As for profitability, AquaBounty Technologies has a trailing twelve months EPS of $-6.8.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.8%.
Moving Average
AquaBounty Technologies’s worth is way below its 50-day moving average of $4.33 and way under its 200-day moving average of $9.30.
Volume
Today’s last reported volume for AquaBounty Technologies is 34200 which is 15.8% above its average volume of 29533.
Earnings Before Interest, Taxes, Depreciation, and Amortization
AquaBounty Technologies’s EBITDA is 6.49.
Sales Growth
AquaBounty Technologies’s sales growth is negative 32.7% for the current quarter and 115.1% for the next.
More news about AquaBounty Technologies.
7. Allakos (ALLK) – -9.33%
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
NASDAQ ended the session with Allakos dropping 9.33% to $2.04 on Wednesday while NASDAQ rose 0.9% to $13,639.86.
Earnings Per Share
As for profitability, Allakos has a trailing twelve months EPS of $-1.32.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -63.35%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Allakos’s EBITDA is -4.48.
More news about Allakos.
8. Atomera Incorporated (ATOM) – -8.99%
Atomera Incorporated develops, commercializes, and licenses proprietary materials, processes, and technologies for the semiconductor industry in North America, Europe, and the Asia Pacific. The company's lead technology is the Mears Silicon Technology, a thin film of reengineered silicon that can be applied as a transistor channel enhancement to CMOS-type transistors. Its customers include foundries, integrated device manufacturers, fabless semiconductor manufacturers, original equipment manufacturers, and electronic design automation companies. The company was formerly known as Mears Technologies, Inc. and changed its name to Atomera Incorporated in January 2016. Atomera Incorporated was incorporated in 2001 and is headquartered in Los Gatos, California.
NASDAQ ended the session with Atomera Incorporated falling 8.99% to $5.32 on Wednesday, after four consecutive sessions in a row of losses. NASDAQ jumped 0.9% to $13,639.86, after five successive sessions in a row of gains, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Atomera Incorporated has a trailing twelve months EPS of $-0.8.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.46%.
More news about Atomera Incorporated.
9. Akoustis Technologies (AKTS) – -8.92%
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.
NASDAQ ended the session with Akoustis Technologies dropping 8.92% to $0.59 on Wednesday while NASDAQ jumped 0.9% to $13,639.86.
Earnings Per Share
As for profitability, Akoustis Technologies has a trailing twelve months EPS of $-0.92.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -67.02%.
Yearly Top and Bottom Value
Akoustis Technologies’s stock is valued at $0.59 at 01:32 EST, way below its 52-week high of $4.96 and way above its 52-week low of $0.46.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Akoustis Technologies’s EBITDA is -12.75.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 35.7% and 15.8%, respectively.
More news about Akoustis Technologies.
10. POSCO (PKX) – -8.7%
POSCO Holdings Inc., together with its subsidiaries, manufactures and sells iron and steel rolled products in South Korea and internationally. It operates in two segments Steel and Others. The company offers hot and cold rolled steel, steel plates, wire rods, galvanized steel, electrical steel, stainless steel, and titanium. It is also involved in the e-commerce business; processing and sale of steel by-products; and provision of business support, and office administration and management consulting services. The company serves automotive, construction, shipbuilding, energy, home appliances, and industrial machinery applications. POSCO Holdings Inc. was incorporated in 1968 and is headquartered in Pohang, South Korea.
NYSE ended the session with POSCO dropping 8.7% to $88.56 on Wednesday, after five consecutive sessions in a row of gains. NYSE slid 0.35% to $15,386.01, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.
Earnings Per Share
As for profitability, POSCO has a trailing twelve months EPS of $3.2.
PE Ratio
POSCO has a trailing twelve months price to earnings ratio of 27.67. Meaning, the purchaser of the share is investing $27.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.48%.
Volatility
POSCO’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.96%, a negative 1.01%, and a positive 2.33%.
POSCO’s highest amplitude of average volatility was 2.99% (last week), 3.02% (last month), and 2.33% (last quarter).
Volume
Today’s last reported volume for POSCO is 234608 which is 7.01% above its average volume of 219228.
More news about POSCO.
Stay up to date with our winners and losers daily report
